Cat. No.: HY-14589

Copy Link Print Information

Chrysin

(Synonyms: 5,7-Dihydroxyflavone)

16 Cited Publications

Customer Review

Based on 16 publication(s) in Google Scholar

Chrysin is one of the most well known estrogen blockers.

For research use only. We do not sell to patients.

Purity: 99.75%
CAS No.: 480-40-0
Formula: C₁₅H₁₀O₄
Molecular Weight:254.24

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Chrysin Chemical Structure

CAS No.: 480-40-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (16)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Chrysin is one of the most well known estrogen blockers.

IC₅₀ & Target

estrogen

All Estrogen Receptor/ERR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	28.62 μM Compound: 2, Chry	Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A-375	IC₅₀	29.65 μM Compound: 8	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 19782567]
A-375	IC₅₀	33.23 μM Compound: 2, Chry	Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A-431	IC₅₀	29.39 μM Compound: 2, Chry	Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A-431	IC₅₀	60.13 μM Compound: 2, Chry	Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
A549	EC₅₀	233 μM Compound: 3	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 12027739]
A549	IC₅₀	19.88 μM Compound: 8	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 19782567]
A549	IC₅₀	47.8 μM Compound: Chrysin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30031652]
A549	IC₅₀	>50 μM Compound: Chrysin	Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 31615696]
A549	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 32160978]
A549	IC₅₀	28 μM Compound: Chrysin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
B16-BL6	EC₅₀	74.4 μM Compound: 3	Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 12027739]
B16-F10	IC₅₀	17.45 μM Compound: Chrysin	Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay	[PMID: 30031652]
BALB/3T3	IC₅₀	248.2 μM Compound: 2	Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay	[PMID: 10096863]
BXPC-3	IC₅₀	54.27 μM Compound: 2, Chry	Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
C13	IC₅₀	49.66 μM Compound: 2, Chry	Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
C8166	CC₅₀	110 μg/mL Compound: 5	Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24794743]
C8166	EC₅₀	13.4 μg/mL Compound: 5	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis	[PMID: 24794743]
Caco-2	IC₅₀	9.5 μM Compound: 23	Cytotoxicity in human Caco2 cells after 72 hrs by MTT assay Cytotoxicity in human Caco2 cells after 72 hrs by MTT assay	[PMID: 28793973]
DLD-1	IC₅₀	18.62 μM Compound: 4	Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay Antiproliferative activity against human DLD1 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
DU-145	IC₅₀	9.81 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) DU145 cells by MTT assay Cytotoxicity against Homo sapiens (human) DU145 cells by MTT assay	10.1007/s00044-010-9395-1
H22	IC₅₀	1671 μM Compound: 1, Chrysin	Cytotoxicity against mouse H22 cells assessed as growth inhibition by MTT assay Cytotoxicity against mouse H22 cells assessed as growth inhibition by MTT assay	[PMID: 24556144]
H9	EC₅₀	5 μM Compound: 11	Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay	[PMID: 8158164]
H9	IC₅₀	47 μM Compound: 11	Cytotoxicity against human H9 cells after 3 days Cytotoxicity against human H9 cells after 3 days	[PMID: 8158164]
H9	EC₅₀	5 μg/mL Compound: F4	Effective dose against H9 cell lines Effective dose against H9 cell lines	[PMID: 8642556]
HCT-116	IC₅₀	>100 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) HCT116 cells by MTT assay Cytotoxicity against Homo sapiens (human) HCT116 cells by MTT assay	10.1007/s00044-010-9395-1
HCT-15	IC₅₀	54.43 μM Compound: 2, Chry	Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
HEK293	IC₅₀	77.45 μM Compound: 2, Chry	Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
HEK-293T	IC₅₀	319.36 μM Compound: Chrysin	Cytotoxicity against human 293T cells after 48 hrs by MTT assay Cytotoxicity against human 293T cells after 48 hrs by MTT assay	[PMID: 30031652]
HeLa	EC₅₀	111 μM Compound: 3	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 12027739]
HeLa	IC₅₀	≥10 μM Compound: chrysin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19278239]
HeLa	IC₅₀	2.9 x 10^-5 M Compound: 1	Cytotoxicity against human HeLa cells after 72 hrs by XTT assay Cytotoxicity against human HeLa cells after 72 hrs by XTT assay	[PMID: 20619940]
HeLa	IC₅₀	10.93 μg/mL Compound: Chrysin	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 26514745]
HeLa	IC₅₀	14.2 μM Compound: Chrysin	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	[PMID: 28797675]
HeLa	IC₅₀	25.05 μM Compound: Chrysin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30031652]
HeLa	IC₅₀	43 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay Cytotoxicity against Homo sapiens (human) HeLa cells by MTT assay	10.1007/s00044-010-9395-1
HepG2	IC₅₀	>100 μM Compound: Chrysin	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26896708]
HepG2	IC₅₀	16.5 μM Compound: 4	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
HL-60	IC₅₀	33.98 μM Compound: 8	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19782567]
HT-1080	EC₅₀	94.9 μM Compound: 3	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 12027739]
HT-29	IC₅₀	3.1 μM Compound: 1	In vitro inhibitory concentration required against human colorectal adenocarcinoma HT-29 cell line In vitro inhibitory concentration required against human colorectal adenocarcinoma HT-29 cell line	[PMID: 12617913]
HT-29	IC₅₀	19.49 μM Compound: 4	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
Huh-7	CC₅₀	>50 μM Compound: 18	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Jurkat	IC₅₀	4.9 μM Compound: Chrysin	Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method	[PMID: 30776692]
Jurkat	IC₅₀	6.1 μM Compound: Chrysin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method	[PMID: 30776692]
K562	IC₅₀	>50 μM Compound: Chrysin	Antiproliferative activity against human K562 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 31615696]
K562	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 32160978]
K562	IC₅₀	>100 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) K562 cells by MTT assay Cytotoxicity against Homo sapiens (human) K562 cells by MTT assay	10.1007/s00044-010-9395-1
KB	IC₅₀	29.6 μM Compound: Chrysin	Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
KB	ED₅₀	13 μg/mL Compound: NSC-407436	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 469554]
KYSE-510	IC₅₀	63 μM Compound: Chrysin	Cytotoxicity in human KYSE-510 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay Cytotoxicity in human KYSE-510 cells assessed as reduction in cell viability incubated for 24 to 72 hrs by MTT assay	[PMID: 28797675]
L02	IC₅₀	>100 μM Compound: Chrysin	Cytotoxicity against human LO2 cells after 48 hrs by MTT assay Cytotoxicity against human LO2 cells after 48 hrs by MTT assay	[PMID: 26896708]
MCF7	IC₅₀	2.6 μM Compound: 10	Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining	[PMID: 21354800]
MCF7	IC₅₀	50.32 μM Compound: 2, Chry	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
MCF7	IC₅₀	25.66 μM Compound: Chrysin	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30031652]
MCF7	IC₅₀	50 nM Compound: Chrysin	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MCF7	IC₅₀	26.9 μM Compound: Chrysin	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
MCF7	GI₅₀	69 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay	10.1007/s00044-012-0423-1
MDA-MB-231	IC₅₀	33 μM Compound: Chrysin	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 34171512]
MDCK	IC₅₀	1.5 μM Compound: 10	Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining	[PMID: 21354800]
Mesenchymal stem cells	EC₅₀	77.7 μM Compound: 1	Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay	[PMID: 37077388]
MOLT-4	GI₅₀	58.6 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay	10.1007/s00044-012-0423-1
Monocyte	IC₅₀	2.4 μM Compound: chrysin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
Monocyte	IC₅₀	2.4 x 10^-6 M Compound: chrysin	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
MRC5	IC₅₀	>100 μM Compound: Chrysin	Cytotoxicity against human MRC5 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 31615696]
MRC5	IC₅₀	>100 μM Compound: 1	Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 32160978]
NCI/ADR-RES	IC₅₀	51.04 μM Compound: 2, Chry	Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 25906385]
NCI-H1299	IC₅₀	>50 μM Compound: Chrysin	Antiproliferative activity against human H1299 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human H1299 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 31615696]
NCI-H1299	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 32160978]
Neutrophil	IC₅₀	53 μM Compound: 4a	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	9.59 μM Compound: 4a	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	2.25 μM Compound: 23	Inhibition of fMLF-induced chemotaxis in human neutrophils pretreated for 45 mins followed by fMLF-stimulation measured for 1 hr by luminescence based analysis Inhibition of fMLF-induced chemotaxis in human neutrophils pretreated for 45 mins followed by fMLF-stimulation measured for 1 hr by luminescence based analysis	[PMID: 37683361]
PC-3	IC₅₀	>50 μM Compound: Chrysin	Antiproliferative activity against human PC3 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell proliferation incubated for 48 hrs by MTT assay	[PMID: 31615696]
PC-3	IC₅₀	>50 μM Compound: 1	Antiproliferative activity against human PC3 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay	[PMID: 32160978]
RBL-2H3	IC₅₀	>500 μM Compound: 11	Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge	[PMID: 14510616]
RD	EC₅₀	15.89 μM Compound: CR	Antiviral activity against EV71 infected in human RD cells assessed as protection against virus infection after 72 hrs by MTS assay Antiviral activity against EV71 infected in human RD cells assessed as protection against virus infection after 72 hrs by MTS assay	[PMID: 27776325]
SGC-7901	IC₅₀	5.8 μM Compound: 1	In vitro inhibitory concentration required against human gastric adenocarcinoma SGC-7901 cell line In vitro inhibitory concentration required against human gastric adenocarcinoma SGC-7901 cell line	[PMID: 12617913]
SGC-7901	IC₅₀	>100 μM Compound: Chrysin	Cytotoxicity against Homo sapiens (human) SGC7901 cells by MTT assay Cytotoxicity against Homo sapiens (human) SGC7901 cells by MTT assay	10.1007/s00044-010-9395-1
SW1353	IC₅₀	33 μM Compound: 4	Antiinflammatory activity in PMA-stimulated human SW1353 cells assessed as inhibition of NF-kappaB activation Antiinflammatory activity in PMA-stimulated human SW1353 cells assessed as inhibition of NF-kappaB activation	[PMID: 19555121]
SW480	IC₅₀	31.08 μM Compound: 4	Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay	10.1039/C5MD00163C
T-cell	CC₅₀	428.27 μM Compound: 1, CR	Cytotoxicity against BALB/c mouse T cells after 48 hrs by MTT assay Cytotoxicity against BALB/c mouse T cells after 48 hrs by MTT assay	[PMID: 21131104]
T-cell	IC₅₀	44.16 μM Compound: 1, CR	Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of anti-CD3/anti-CD28-stimulated cell proliferation after 72 hrs by MTT assay Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of anti-CD3/anti-CD28-stimulated cell proliferation after 72 hrs by MTT assay	[PMID: 21131104]
THP-1	IC₅₀	23.38 μM Compound: 8	Cytotoxicity against human THP1 cells by MTT assay Cytotoxicity against human THP1 cells by MTT assay	[PMID: 19782567]
Vero	CC₅₀	76.2 μg/mL Compound: chrysin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 1338212]

In Vitro

Chrysin is mainly found in passion flowers, honey, and propolis acts as a potential therapeutic and preventive agent to inhibit proliferation and invasion of various human cancer cells. Although Chrysin has anti-carcinogenic effects in several cancers, little is known about its functional roles in ovarian cancer which shows poor prognosis and chemoresistance to traditional therapeutic agents. Chrysin inhibits ovarian cancer cell proliferation and induced cell death by increasing reactive oxygen species (ROS) production and cytoplasmic Ca²⁺ levels as well as inducing loss of mitochondrial membrane potential (MMP). Chrysin activates MAPK and PI3K/AKT pathways in ES2 and OV90 cells in concentration-response experiments. Chrysin suppresses tumor growth byregulating canonical Wnt and nuclear factor NF-κB signaling cascades cancer cells.? Chrysin stimulates the phosphorylation of AKT and P70S6K proteins in both ES2 and OV90 cells compared tothe untreated control cells.? In addition, Chrysin activates the phospho-ERK1/2, p38,and JNK proteins as members of the MAPK pathway in the ovarian cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 480-40-0
Appearance Solid
Molecular Weight 254.24
Formula C₁₅H₁₀O₄
Color Light yellow to yellow
SMILES

OC1=C2C(OC(C3=CC=CC=C3)=CC2=O)=CC(O)=C1
Synonyms

5,7-Dihydroxyflavone
Structure Classification
- Flavonoids
- Flavones
- Phenols
- Polyphenols
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (16)

All Cell Migration/Invasion AssayBio/Physico-chemical AssayCell Proliferation/Viability AssayELISAFlow Cytometry

Sort by:

Journal Impact Factor

Acta Pharm Sin B

Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]

2021 Jan;11(1):143-155. PMID: 33532186

Chrysin purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]

Chrysin (10-50 μM; 16 h) dose-dependently inhibited the invasion of the indicated ESCC cells.

Chrysin purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]

Chrysin (10-50 μM) significantly reduced the levels of glycolytic indexes, such as glucose uptake and lactate production compared with control ESCC cells.

Chrysin purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]

Chrysin (10-50 μM; 2 weeks) dose-dependently suppressed the anchorage-dependent colony formation of ESCC cells.

Chrysin purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]

Chrysin (50 μM) stimulated the cleaved PARP expression in ESCC cells.

Chrysin purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]

Chrysin (10-50 μM; 48 h) dose-dependently increased the apoptotic rate in KYSE410, KYSE30, and KYSE150 cells.
Adv Sci (Weinh)

Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor Sizes. [Abstract]

2024 Dec 5:e2410360. PMID: 39639496
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Clin Sci

A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis. [Abstract]

2021 Jul 30;135(14):1751-1765. PMID: 34282832
Ind Crops Prod

2025 Dec 11;239:122458.
Ecotoxicol Environ Saf

Chrysin reshapes ferroptosis sensitivity to reverse nickel refining fumes-induced lung injury via the miR-210/ANGPTL4 signaling axis mediated by the PHD1/HIF-1α pathway. [Abstract]

2026 May 13:318:120239. PMID: 42127541
Int J Mol Med

Chrysin induces autophagy through the inactivation of the ROS‑mediated Akt/mTOR signaling pathway in endometrial cancer. [Abstract]

2021 Sep;48(3):172. PMID: 34278450
Cell Prolif

Flavonoid chrysin activates both TrkB and FGFR1 receptors while upregulates their endogenous ligands such as brain derived neurotrophic factor to promote human neurogenesis. [Abstract]

2025 Jan;58(1):e13732. PMID: 39331585
Mol Neurobiol

Chrysin Improves Cognitive Dysfunction in Rats with Intracerebral Hemorrhage by Regulating the Nrf2/GPX4 Pathway to Inhibit Ferroptosis. [Abstract]

2025 Nov 13;63(1):35. PMID: 41231360
Mol Neurobiol

Dietary Flavonoid Chrysin Functions as a Dual Modulator to Attenuate Amyloid-β and Tau Pathology in the Models of Alzheimer's Disease. [Abstract]

2025 Apr;62(4):4274-4291. PMID: 39432184
Biomedicines

Chrysin Pretreatment Enhances BMSC Therapeutic Efficacy in Resolving Diabetic Wound Healing. [Abstract]

2026 Mar 30;14(4):781. PMID: 42072322
Regen Ther

Chrysin, which targets PLAU, protects PC12 cells from OGD/R-stimulated damage through repressing the NF-κB signaling pathway. [Abstract]

2022 Jan 13:19:69-76. PMID: 35097165
Cell Cycle

Chrysin impairs genomic stability by suppressing DNA double-strand break repair in breast cancer cells. [Abstract]

2022 Feb;21(4):379-391. PMID: 34985375
J Mol Histol

Chrysin inhibits hypertrophic scar formation through TGF-β/Smad signaling pathways. [Abstract]

2025 Sep 6;56(5):298. PMID: 40913688

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (393.33 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9333 mL

19.6665 mL

39.3329 mL

5 mM

0.7867 mL

3.9333 mL

7.8666 mL

10 mM

0.3933 mL

1.9666 mL

3.9333 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 10 mg/mL (39.33 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

The proliferation assays are conducted using a cell proliferation enzyme-linked immunosorbent assay (ELISA) 5-bromo-2'-deoxyuridine (BrdU) kit. Briefly, ES2 and OV90 cells are seeded in a 96-well plate, and then treated with Chrysin (0, 5, 10, 20, 50, and 100 µM) with or without inhibitors (20 μM LY294002, PI3K/AKT; 10 μM U0126, ERK1/2; 10 μM SP600125, JNK; and 20 μM SB203580, p38) in a final volume of 100 μL/well. Aftera48-h incubation, 10 μM BrdU is added to the cell culture, followed by an additional 2-h incubation at 37°C. After labeling the cells with BrdU, they are fixed and then incubated with the anti-BrdU-peroxidase (POD) working solution for 90 min. The anti-BrdU-POD binds to the BrdU incorporated into newly synthesized cellular DNA and these immune complexes are detected by analyzing their reaction with the 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The absorbance values of the reaction product are measured at 370 and 492 nm using an ELISA reader^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lim W, et al. Chrysin Attenuates Progression of Ovarian Cancer Cells by Regulating Signaling Cascades and Mitochondrial Dysfunction. J Cell Physiol. 2017 Aug 17. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9333 mL	19.6665 mL	39.3329 mL	98.3323 mL
	5 mM	0.7867 mL	3.9333 mL	7.8666 mL	19.6665 mL
	10 mM	0.3933 mL	1.9666 mL	3.9333 mL	9.8332 mL
	15 mM	0.2622 mL	1.3111 mL	2.6222 mL	6.5555 mL
	20 mM	0.1967 mL	0.9833 mL	1.9666 mL	4.9166 mL
	25 mM	0.1573 mL	0.7867 mL	1.5733 mL	3.9333 mL
	30 mM	0.1311 mL	0.6555 mL	1.3111 mL	3.2777 mL
	40 mM	0.0983 mL	0.4917 mL	0.9833 mL	2.4583 mL
	50 mM	0.0787 mL	0.3933 mL	0.7867 mL	1.9666 mL
	60 mM	0.0656 mL	0.3278 mL	0.6555 mL	1.6389 mL
	80 mM	0.0492 mL	0.2458 mL	0.4917 mL	1.2292 mL
	100 mM	0.0393 mL	0.1967 mL	0.3933 mL	0.9833 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Chrysin

Natural Product Library

Anti-Cancer Compound Library

Medicine Food Homology Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Nuclear Receptor Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Chrysin

All Estrogen Receptor/ERR Isoforms

Biological Activity

Chemical Information

Publications (16)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Chrysin Related Classifications

HY-14589 Related Classifications